Neos Therapeutics, Inc. (NEOS): Price and Financial Metrics

Neos Therapeutics, Inc. (NEOS)

Today's Latest Price: $0.83 USD

0.10 (-11.08%)

Updated Jan 27 4:00pm

Add NEOS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NEOS Stock Summary

  • Neos Therapeutics Inc's market capitalization of $46,422,960 is ahead of only 10.93% of US-listed equities.
  • Neos Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 3.49% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -5.48 for Neos Therapeutics Inc; that's greater than it is for just 2.97% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Neos Therapeutics Inc are ADMS, TXMD, MNKD, TELA, and ESTA.
  • NEOS's SEC filings can be seen here. And to visit Neos Therapeutics Inc's official web site, go to

NEOS Stock Price Chart Interactive Chart >

Price chart for NEOS

NEOS Price/Volume Stats

Current price $0.83 52-week high $1.98
Prev. close $0.93 52-week low $0.45
Day low $0.82 Volume 4,471,853
Day high $0.93 Avg. volume 5,829,385
50-day MA $0.68 Dividend yield N/A
200-day MA $0.70 Market Cap 41.30M

Neos Therapeutics, Inc. (NEOS) Company Bio

Neos Therapeutics develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The company was founded in 2008 and is based in Grand Prairie, Texas.

NEOS Latest News Stream

Event/Time News Detail
Loading, please wait...

NEOS Latest Social Stream

Loading social stream, please wait...

View Full NEOS Social Stream

Latest NEOS News From Around the Web

Below are the latest news stories about Neos Therapeutics Inc that investors may wish to consider to help them evaluate NEOS as an investment opportunity.

A Specialty Consolidator: Biopharma Aytu Looks To Acquisitions And Licensing To Propel Growth Through 2021

The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.Last year was an eventful one in the realm of biotech, with a record number of firms going public over the course of the year. Aytu BioScience Inc. (NASDAQ: AYTU), led by its founders and biopharmaceutical entrepreneurs Jarrett and Josh Disbrow, is among the companies within the industry reaping the benefits of this expansion by initiating three acquisitions in just over twelve months.Under an executive team helmed by CEO Josh Disbrow, Aytu has implemented an aggressive strategy of acquisition of specialty prescription and...

Yahoo | January 6, 2021

Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference

DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company…

GlobeNewswire | January 4, 2021

Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts

For a company with so many potentially game-changing initiatives underway, a stable full of dynamic leaders, and backing from some very reputable big-money sponsors, Aytu BioScience (AYTU) sure knows how to gaslight its almost cult-like following of die-hard retail investors. To say it has been a rough year for investors...

Swich Research on Seeking Alpha | December 31, 2020

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - PS, BEAT, HCAP, NEOS, HBAN

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | December 29, 2020

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - BEAT, SNCA, BBIO, TLRY, NEOS

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | December 19, 2020

Read More 'NEOS' Stories Here

NEOS Price Returns

1-mo 26.68%
3-mo 18.59%
6-mo 23.59%
1-year -53.37%
3-year -92.59%
5-year -93.89%
YTD 32.86%
2020 -58.63%
2019 -8.48%
2018 -83.82%
2017 74.36%
2016 -59.15%

Continue Researching NEOS

Here are a few links from around the web to help you further your research on Neos Therapeutics Inc's stock as an investment opportunity:

Neos Therapeutics Inc (NEOS) Stock Price | Nasdaq
Neos Therapeutics Inc (NEOS) Stock Quote, History and News - Yahoo Finance
Neos Therapeutics Inc (NEOS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7549 seconds.